Relationship of Sleep to Pulmonary Function in Mucopolysaccharidosis II

Overview

Journal J Pediatr

Specialty Pediatrics

Date 2013 Jan 12

PMID 23305961

Citations 10

Authors

William I Wooten 3rd

Joseph Muenzer

Bradley V Vaughn

Marianne S Muhlebach

Affiliations

Soon will be listed here.

Abstract

Objective: To study the sleep characteristics, pulmonary function, and their relationships in an enzyme naive population of patients with mucopolysaccharidoses (MPS) II (Hunter syndrome).

Study Design: The analyzed subjects (30 patients with MPS II with a median age of 9 years) had been enrolled in an MPS II natural history study and a phase I/II enzyme replacement clinical study in which they underwent standard polysomnography including spirometry and plethysmography, if cooperative. Descriptive statistics and nonparametric correlation were performed for demographic, sleep, and pulmonary function variables.

Results: Median apnea-hypopnea index was 6.4, with obstructive sleep apnea observed in 27/30 subjects. Sleep architecture was characterized by diminished rapid-eye movement sleep duration (median 13%), and decline in sleep efficiency and slow-wave sleep duration in older individuals. Oxygen desaturation below 90% occurred in 26/30 subjects, and hypoventilation above 50 Torr occurred in 11/23 subjects with accurate end-tidal carbon dioxide recordings. Of 15 subjects with reliable spirometry, median forced expiratory volume in 1 second was below 80% predicted in 12/15 subjects. Forced expiratory volume in 1 second in percent-predicted was inversely related to apnea-hypopnea index and increase from baseline end-tidal carbon dioxide (P=.023, rs=-0.58), (P<.001, rs=-0.82).

Conclusion: Sleep in MPS II is characterized by obstructive sleep apnea, altered sleep architecture, and impaired gas exchange. Sleep disruption is related to daytime pulmonary function, thus both systems should be evaluated when sleep abnormalities are suspected.

Citing Articles

The diagnosis and management of mucopolysaccharidosis type II.

Mao S, Chen Q, Dai Y, Dong G, Zou C Ital J Pediatr. 2024; 50(1):207.

PMID: 39380047 PMC: 11463001. DOI: 10.1186/s13052-024-01769-9.

Lung Diseases and Rare Disorders: Is It a Lysosomal Storage Disease? Differential Diagnosis, Pathogenetic Mechanisms and Management.

Montanari C, Tagi V, DAuria E, Guaia V, Di Gallo A, Ghezzi M Children (Basel). 2024; 11(6).

PMID: 38929247 PMC: 11201433. DOI: 10.3390/children11060668.

Airway and Anaesthetic Management of Adult Patients with Mucopolysaccharidoses Undergoing Cardiac Surgery.

Mayhew D, Palmer K, Wilson I, Watson S, Stepien K, Jenkins P J Clin Med. 2024; 13(5).

PMID: 38592237 PMC: 10932343. DOI: 10.3390/jcm13051366.

Respiratory Dysfunction in Children and Adolescents with Mucopolysaccharidosis Types I, II, IVA, and VI.

Tulebayeva A, Sharipova M, Boranbayeva R Diagnostics (Basel). 2020; 10(2).

PMID: 31991612 PMC: 7168931. DOI: 10.3390/diagnostics10020063.

Sleep-disordered breathing in paediatric setting: existing and upcoming of the genetic disorders.

Zaffanello M, Antoniazzi F, Tenero L, Nosetti L, Piazza M, Piacentini G Ann Transl Med. 2018; 6(17):343.

PMID: 30306082 PMC: 6174189. DOI: 10.21037/atm.2018.07.13.

References

Eigen H, Bieler H, Grant D, Christoph K, Terrill D, Heilman D . Spirometric pulmonary function in healthy preschool children. Am J Respir Crit Care Med. 2001; 163(3 Pt 1):619-23. DOI: 10.1164/ajrccm.163.3.2002054. View

Sans Capdevila O, Kheirandish-Gozal L, Dayyat E, Gozal D . Pediatric obstructive sleep apnea: complications, management, and long-term outcomes. Proc Am Thorac Soc. 2008; 5(2):274-82. PMC: 2645258. DOI: 10.1513/pats.200708-138MG. View

Fraser J, Wraith J, Delatycki M . Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians. Clin Genet. 2002; 62(5):418-21. DOI: 10.1034/j.1399-0004.2002.620512.x. View

Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox G . Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2009; 99(1):18-25. DOI: 10.1016/j.ymgme.2009.08.006. View

Bradley S, Solin P, Wilson J, Johns D, Walters E, Naughton M . Hypoxemia and hypercapnia during exercise and sleep in patients with cystic fibrosis. Chest. 1999; 116(3):647-54. DOI: 10.1378/chest.116.3.647. View

Mokhlesi B, Tulaimat A . Recent advances in obesity hypoventilation syndrome. Chest. 2007; 132(4):1322-36. DOI: 10.1378/chest.07-0027. View

Kuczmarski R, Ogden C, Grummer-Strawn L, Flegal K, Guo S, Wei R . CDC growth charts: United States. Adv Data. 2001; (314):1-27. View

Scholle S, Wiater A, Scholle H . Normative values of polysomnographic parameters in childhood and adolescence: arousal events. Sleep Med. 2012; 13(3):243-51. DOI: 10.1016/j.sleep.2011.07.022. View

John A, Fagondes S, Schwartz I, Azevedo A, Barrios P, Dalcin P . Sleep abnormalities in untreated patients with mucopolysaccharidosis type VI. Am J Med Genet A. 2011; 155A(7):1546-51. DOI: 10.1002/ajmg.a.33902. View

10.

Hankinson J, Odencrantz J, Fedan K . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999; 159(1):179-87. DOI: 10.1164/ajrccm.159.1.9712108. View

11.

Martins A, Dualibi A, Norato D, Takata E, Santos E, Valadares E . Guidelines for the management of mucopolysaccharidosis type I. J Pediatr. 2009; 155(4 Suppl):S32-46. DOI: 10.1016/j.jpeds.2009.07.005. View

12.

Chebbo A, Tfaili A, Jones S . Hypoventilation syndromes. Med Clin North Am. 2011; 95(6):1189-202. DOI: 10.1016/j.mcna.2011.09.002. View

13.

Muenzer J, Bodamer O, Burton B, Clarke L, Frenking G, Giugliani R . The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr. 2011; 171(1):181-8. PMC: 3249184. DOI: 10.1007/s00431-011-1606-3. View

14.

Muhlebach M, Shaffer C, Georges L, Abode K, Muenzer J . Bronchoscopy and airway management in patients with mucopolysaccharidoses (MPS). Pediatr Pulmonol. 2012; 48(6):601-7. DOI: 10.1002/ppul.22629. View

15.

Muenzer J, Beck M, Eng C, Escolar M, Giugliani R, Guffon N . Multidisciplinary management of Hunter syndrome. Pediatrics. 2009; 124(6):e1228-39. DOI: 10.1542/peds.2008-0999. View

16.

Leighton S, Papsin B, Vellodi A, Dinwiddie R, Lane R . Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001; 58(2):127-38. DOI: 10.1016/s0165-5876(01)00417-7. View

17.

Lin H, Chen M, Lin C, Chen C, Lin D, Chuang C . Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol. 2010; 45(12):1205-12. DOI: 10.1002/ppul.21309. View

18.

Santamaria F, Andreucci M, Parenti G, Polverino M, Viggiano D, Montella S . Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings. J Inherit Metab Dis. 2007; 30(5):743-9. DOI: 10.1007/s10545-007-0555-5. View

19.

Muhlebach M, Wooten W, Muenzer J . Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev. 2011; 12(2):133-8. DOI: 10.1016/j.prrv.2010.10.005. View

20.

Muenzer J, Gucsavas-Calikoglu M, McCandless S, Schuetz T, Kimura A . A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2006; 90(3):329-37. DOI: 10.1016/j.ymgme.2006.09.001. View